Adenosine-5'-diphosphate
(Synonyms: 二磷酸腺苷,Adenosine Pyrophosphate,ADP,5′-ADP) 目录号 : GC11969
Adenosine-5'-diphosphate是 P2Y1、P2Y12、P2Y13 等嘌呤能 P2Y 受体的天然激动剂，可直接结合并触发下游信号级联。
Cas No.:58-64-0
Sample solution is provided at 25 µL, 10mM.
Adenosine-5'-diphosphate is a natural agonist for the purinergic P2Y receptors, including P2Y1, P2Y12, and P2Y13, and can directly bind to and trigger downstream signaling cascades[1]. Purinergic receptors are a class of membrane molecules present in almost all mammalian tissues and are involved in various cellular functions, including cell proliferation and migration, vascular reactivity, apoptosis, and cytokine secretion[2]. Adenosine-5'-diphosphate is a natural purine nucleotide composed of a pyrophosphate group, ribose, and adenine, and is the main product of ATP dephosphorylation by ATPase and can be rephosphorylated to ATP by ATP synthase[3]. As a downstream metabolite of ATP, Adenosine-5'-diphosphate activates purinergic receptors to participate in multiple cellular processes, such as respiration, biosynthetic reactions, cell movement, cell division, and the proliferation and migration of neural stem cells, and is commonly used to study platelet aggregation, antithrombotic mechanisms, and cellular energy metabolism[4][5].
In vitro, treatment of fibroblast-like synoviocyte (FLS) cells with Adenosine-5'-diphosphate (100µM) for 24h significantly induces monocyte chemotactic protein 1 (MCP-1)/ C–C motif chemokine ligand 2 (CCL2) expression via P2Y13 receptors in an MEK/ERK-dependent manner[6].
In vivo, intravenous Adenosine-5'-diphosphate infusions of 2, 4, 8mg/kg/hour during 3 subsequent 20-minute periods in anesthetized Wistar rats induces systemic and renal vasodilation, leading to a gradual, dose-dependent 15% decrease in mean arterial pressure, a sustained increase in renal blood flow, and a 25% decrease in renal vascular resistance, while renal medullary perfusion remains unaffected[7].
References:
[1] Li Y, Yin C, Liu P, Li D, Lin J. Identification of a Different Agonist-Binding Site and Activation Mechanism of the Human P2Y1 Receptor. Sci Rep. 2017;7(1):13764.
[2] Huang Z, Xie N, Illes P, et al. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther. 2021;6(1):162.
[3] Bjelobaba I, Janjic MM, Stojilkovic SS. Purinergic signaling pathways in endocrine system. Auton Neurosci. 2015;191:102-116.
[4] Liu Y, Niu H, Wang C, et al. Bio-inspired, bio-degradable adenosine 5'-diphosphate-modified hyaluronic acid coordinated hydrophobic undecanal-modified chitosan for hemostasis and wound healing. Bioact Mater. 2022;17:162-177.
[5] Jacobson KA, Ivanov AA, de Castro S, Harden TK, Ko H. Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal. 2009;5(1):75-89.
[6] Yokota S, Chosa N, Matsumoto S, Satoh K, Ishisaki A. Extracellular adenosine 5'-diphosphate promotes MCP-1/CCL2 expression via the P2Y13 purinergic receptor/ERK signaling axis in temporomandibular joint-derived mouse fibroblast-like synoviocytes. Mol Biol Rep. 2023;50(2):1595-1602.
[7] Roszkowska-Chojecka MM, Walkowska A, Sadowski J, Dobrowolski L. Clopidogrel Partially Counteracts Adenosine-5'-Diphosphate Effects on Blood Pressure and Renal Hemodynamics and Excretion in Rats. Am J Med Sci. 2018;356(3):287-295.
Adenosine-5'-diphosphate是P2Y1、P2Y12、P2Y13等嘌呤能P2Y受体的天然激动剂，可直接结合并触发下游信号级联[1]。嘌呤能受体是一类存在于几乎所有哺乳动物组织中的质膜分子，可参与多种细胞功能，包括细胞的增殖和迁移、血管反应性、细胞凋亡和细胞因子分泌[2]。Adenosine-5'-diphosphate是由焦磷酸基团、戊糖核糖和腺嘌呤构成的天然嘌呤核苷酸，是ATP酶对ATP去磷酸化的主要产物，也可经ATP合酶重新磷酸化为ATP[3]。作为ATP的下游代谢物，Adenosine-5'-diphosphate通过激活嘌呤能受体参与呼吸、生物合成反应、细胞运动、细胞分裂及神经干细胞增殖、迁移等多种细胞过程，常用于研究血小板聚集、抗血栓机制及细胞能量代谢[4][5]。
体外研究中，用100µM的Adenosine-5'-diphosphate处理成纤维样滑膜细胞（FLS）24小时，可通过P2Y13受体显著诱导单核细胞趋化蛋白1（MCP-1）/C-C基序趋化因子配体2（CCL2）的表达，且该过程依赖于MEK/ERK信号通路[6]。
体内研究中，在麻醉的Wistar大鼠中，通过静脉输注Adenosine-5'-diphosphate（剂量分别为2、4、8mg/kg/hour，持续3个20分钟的周期），可诱导全身和肾脏血管扩张，导致平均动脉压逐渐、剂量依赖性地降低15%，肾血流持续增加，肾血管阻力降低25%，而肾髓质灌注未受影响[7]。
| Cell experiment [1]: | |
Cell lines | Fibroblast-like synoviocyte 1 (FLS1) cells |
Preparation Method | FLS1 cells were cultured in Ham’s F-12 medium containing 10% FBS, 2mM glutamine, 100U/mL penicillin, and 100 µg/mL streptomycin. To evaluate MCP-1/CCL2 mRNA expression, these cells were treated with 100µM Adenosine-5'-diphosphate for 24h. Prior to Adenosine-5'-diphosphate administration, the cells were pre-treated for 30min with P2Y purinergic receptor antagonists MRS 2179, AR-C 66096, and MRS 2211 to evaluate the effects of these antagonists on the Adenosine-5'-diphosphate-induced promotion of MCP-1/CCL2 expression. |
Reaction Conditions | 100μM; 24h |
Applications | Adenosine-5'-diphosphate significantly induces monocyte chemotactic protein 1 (MCP-1)/ C–C motif chemokine ligand 2 (CCL2) expression via P2Y13 receptors in an MEK/ERK-dependent manner. |
| Animal experiment [2]: | |
Animal models | Wistar rats |
Preparation Method | Male Wistar normotensive rats weighing 220-245g were accustomed to the housing during a few days preceding chronic experiments. Rats were maintained under controlled temperature (22°C-24°C) at 40-60% humidity in a 12/12 hour light/dark cycle. Adenosine-5'-diphosphate(ADP) was applied in the rats that were either untreated (ADP group; n=6) or chronically pretreated with clopidogrel (Clo+ADP group; n=7). After the equilibration period, 2 30-minute control saline infusion periods were performed, followed by infusion of Adenosine-5'-diphosphate at 2, 4 and 8mg/kg/hour during 3 subsequent 20-minute periods, respectively. After cessation of drug infusion, 3 30-minute saline infusion recovery periods were performed. In a parallel time-control group, ADP was replaced by saline (n=6). Urine volume was determined gravimetrically. Urinary and plasma osmolality (Uosm, Posm) were measured using a cryoscopic osmometer. |
Dosage form | 2, 4 and 8mg/kg/hour during 3 subsequent 20-minute periods; intravenous infusion |
Applications | Adenosine-5'-diphosphate induces systemic and renal vasodilation, leading to a decrease in mean arterial pressure and renal vascular resistance, while increasing renal blood flow. |
References: | |
| Cas No. | 58-64-0 | SDF | |
| 别名 | 二磷酸腺苷,Adenosine Pyrophosphate,ADP,5′-ADP | ||
| 化学名 | adenosine 5'-(trihydrogen diphosphate) | ||
| Canonical SMILES | O[C@H]1[C@H](N2C=NC3=C2N=CN=C3N)O[C@H](COP(OP(O)(O)=O)(O)=O)[C@H]1O | ||
| 分子式 | C10H15N5O10P2 | 分子量 | 427.2 |
| 溶解度 | ≥ 21.35mg/mL in DMSO with gentle warming; 40 mg/mL in Water | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3408 mL | 11.7041 mL | 23.4082 mL |
| 5 mM | 0.4682 mL | 2.3408 mL | 4.6816 mL |
| 10 mM | 0.2341 mL | 1.1704 mL | 2.3408 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
